Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTBEAM-U01 Substudy 01A of zilovertamab vedotin in pediatric and young adult hematologic malignancies or solid tumors
NL-OMON59433Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of zilovertamab vedotin in B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) and 2 more (2 arms), sponsored by Merck & Co. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)neuroblastomaEwing sarcoma
Beyond the preview
Go deeper on NL-OMON59433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59433.